| Disease ID | Disease name | Source of annotation with ADCY6 | OMIM link | Number of associated genes | genes |
|---|---|---|---|---|---|
| PS253310 | LETHAL CONGENITAL CONTRACTURE SYNDROME | ClinVar, OMIM, HUMSAVAR | link to OMIM | 9 | MYBPC1, ZBTB42, ERBB3, GLE1, ADGRG6, CNTNAP1, DNM2, PIP5K1C, ADCY6 |
Download the gene annotation in CSV format
| KEGG pathway | KEGG ID | KEGG IC |
|---|---|---|
| Platelet activation | hsa04611 | 5.66 |
| cGMP-PKG signaling pathway | hsa04022 | 5.32 |
| cAMP signaling pathway | hsa04024 | 5.05 |
| Retrograde endocannabinoid signaling | hsa04723 | 6.03 |
| Cholinergic synapse | hsa04725 | 5.88 |
| Taste transduction | hsa04742 | 6.99 |
| GABAergic synapse | hsa04727 | 6.24 |
| Dilated cardiomyopathy | hsa05414 | 6.08 |
| Oxytocin signaling pathway | hsa04921 | 5.4 |
| Vasopressin-regulated water reabsorption | hsa04962 | 7.18 |
| Endocrine and other factor-regulated calcium reabsorption | hsa04961 | 7.12 |
| Chemokine signaling pathway | hsa04062 | 5.19 |
| HTLV-I infection | hsa05166 | 4.59 |
| Vascular smooth muscle contraction | hsa04270 | 5.74 |
| Gap junction | hsa04540 | 6.24 |
| Pathways in cancer | hsa05200 | 3.98 |
| Oocyte meiosis | hsa04114 | 5.91 |
| GnRH signaling pathway | hsa04912 | 6.18 |
| Ovarian steroidogenesis | hsa04913 | 7.07 |
| Rap1 signaling pathway | hsa04015 | 4.97 |
| Insulin secretion | hsa04911 | 6.18 |
| Inflammatory mediator regulation of TRP channels | hsa04750 | 6.07 |
| Progesterone-mediated oocyte maturation | hsa04914 | 6.18 |
| Estrogen signaling pathway | hsa04915 | 6.11 |
| Thyroid hormone synthesis | hsa04918 | 6.56 |
| Circadian entrainment | hsa04713 | 6.11 |
| Salivary secretion | hsa04970 | 6.23 |
| Gastric acid secretion | hsa04971 | 6.48 |
| Pancreatic secretion | hsa04972 | 6.07 |
| Bile secretion | hsa04976 | 6.56 |
| Morphine addiction | hsa05032 | 6.15 |
| Purine metabolism | hsa00230 | 5.28 |
| Melanogenesis | hsa04916 | 5.97 |
| Adrenergic signaling in cardiomyocytes | hsa04261 | 5.44 |
| Glutamatergic synapse | hsa04724 | 5.84 |
| REACTOME pathway | REACTOME ID | REACTOME IC |
|---|---|---|
| Phospholipase C-mediated cascade; FGFR2 | R-HSA-5654221 | 7.37 |
| PLCG1 events in ERBB2 signaling | R-HSA-1251932 | 7.85 |
| DAG and IP3 signaling | R-HSA-1489509 | 7.98 |
| Phospholipase C-mediated cascade; FGFR3 | R-HSA-5654227 | 7.52 |
| Ca-dependent events | R-HSA-111996 | 8.18 |
| Phospholipase C-mediated cascade; FGFR4 | R-HSA-5654228 | 7.46 |
| G alpha (z) signalling events | R-HSA-418597 | 7.46 |
| Immune System | R-HSA-168256 | 2.37 |
| Transmembrane transport of small molecules | R-HSA-382551 | 3.79 |
| Metabolism | R-HSA-1430728 | 2.34 |
| Downstream signal transduction | R-HSA-186763 | 4.65 |
| Signaling by Hedgehog | R-HSA-5358351 | 5.79 |
| Adenylate cyclase activating pathway | R-HSA-170660 | 9.66 |
| Vasopressin regulates renal water homeostasis via Aquaporins | R-HSA-432040 | 7.56 |
| G alpha (s) signalling events | R-HSA-418555 | 5.99 |
| Calmodulin induced events | R-HSA-111933 | 8.28 |
| Adenylate cyclase inhibitory pathway | R-HSA-170670 | 9.18 |
| PKA-mediated phosphorylation of CREB | R-HSA-111931 | 8.89 |
| Downstream signaling of activated FGFR1 | R-HSA-5654687 | 4.71 |
| CaM pathway | R-HSA-111997 | 8.28 |
| PKA activation | R-HSA-163615 | 8.98 |
| Signalling by NGF | R-HSA-166520 | 4.23 |
| Adrenaline,noradrenaline inhibits insulin secretion | R-HSA-400042 | 8.18 |
| PKA activation in glucagon signalling | R-HSA-164378 | 8.89 |
| GABA receptor activation | R-HSA-977443 | 7.2 |
| Phospholipase C-mediated cascade: FGFR1 | R-HSA-5654219 | 7.43 |
| G alpha (i) signalling events | R-HSA-418594 | 5.1 |
| Neuronal System | R-HSA-112316 | 4.82 |
| Signaling by GPCR | R-HSA-372790 | 2.68 |
| Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell | R-HSA-112314 | 5.85 |
| Transmission across Chemical Synapses | R-HSA-112315 | 5.28 |
| Signaling by FGFR4 | R-HSA-5654743 | 4.69 |
| Signaling by FGFR3 | R-HSA-5654741 | 4.69 |
| Signaling by FGFR | R-HSA-190236 | 4.67 |
| Downstream signaling of activated FGFR3 | R-HSA-5654708 | 4.71 |
| GPCR downstream signaling | R-HSA-388396 | 3.07 |
| GABA B receptor activation | R-HSA-977444 | 7.7 |
| Innate Immune System | R-HSA-168249 | 3.17 |
| Integration of energy metabolism | R-HSA-163685 | 6.24 |
| Aquaporin-mediated transport | R-HSA-445717 | 7.31 |
| Signaling by ERBB2 | R-HSA-1227986 | 4.66 |
| Activation of GABAB receptors | R-HSA-991365 | 7.7 |
| DAP12 signaling | R-HSA-2424491 | 4.64 |
| Hedgehog 'off' state | R-HSA-5610787 | 6.19 |
| Downstream signaling of activated FGFR2 | R-HSA-5654696 | 4.71 |
| PLC-gamma1 signalling | R-HSA-167021 | 7.89 |
| Signaling by EGFR | R-HSA-177929 | 4.59 |
| NGF signalling via TRKA from the plasma membrane | R-HSA-187037 | 4.51 |
| Glucagon signaling in metabolic regulation | R-HSA-163359 | 7.94 |
| EGFR interacts with phospholipase C-gamma | R-HSA-212718 | 7.89 |
| Regulation of insulin secretion | R-HSA-422356 | 6.66 |
| PLC beta mediated events | R-HSA-112043 | 7.52 |
| G-protein mediated events | R-HSA-112040 | 7.49 |
| Signaling by FGFR2 | R-HSA-5654738 | 4.68 |
| Signaling by FGFR1 | R-HSA-5654736 | 4.69 |
| Opioid Signalling | R-HSA-111885 | 6.64 |
| DAP12 interactions | R-HSA-2172127 | 4.56 |
| Inhibition of adenylate cyclase pathway | R-HSA-997269 | 9.18 |
| Downstream signaling of activated FGFR4 | R-HSA-5654716 | 4.71 |
| Signaling by PDGF | R-HSA-186797 | 4.53 |
| Signal Transduction | R-HSA-162582 | 1.78 |
| Glucagon-like Peptide-1 (GLP1) regulates insulin secretion | R-HSA-381676 | 7.59 |
| GO term | GO ID | GO IC |
|---|---|---|
| purine ribonucleoside triphosphate binding | GO:0035639 | 2.22 |
| enzyme binding | GO:0019899 | 2.27 |
| adenylate cyclase activity | GO:0004016 | 6.74 |
| binding | GO:0005488 | 0.18 |
| ion binding | GO:0043167 | 1.36 |
| heterocyclic compound binding | GO:1901363 | 1.06 |
| purine nucleoside binding | GO:0001883 | 2.22 |
| nucleoside binding | GO:0001882 | 2.21 |
| cation binding | GO:0043169 | 1.4 |
| lyase activity | GO:0016829 | 4.53 |
| phosphorus-oxygen lyase activity | GO:0016849 | 6.6 |
| nucleotide binding | GO:0000166 | 1.96 |
| nucleoside phosphate binding | GO:1901265 | 1.96 |
| ribonucleoside binding | GO:0032549 | 2.22 |
| purine nucleotide binding | GO:0017076 | 2.19 |
| metal ion binding | GO:0046872 | 1.41 |
| ATP binding | GO:0005524 | 2.43 |
| small molecule binding | GO:0036094 | 1.89 |
| kinase binding | GO:0019900 | 3.32 |
| protein kinase binding | GO:0019901 | 3.44 |
| adenyl nucleotide binding | GO:0030554 | 2.4 |
| cyclase activity | GO:0009975 | 6.6 |
| organic cyclic compound binding | GO:0097159 | 1.05 |
| catalytic activity | GO:0003824 | 1.05 |
| carbohydrate derivative binding | GO:0097367 | 2.03 |
| adenyl ribonucleotide binding | GO:0032559 | 2.41 |
| protein binding | GO:0005515 | 0.46 |
| purine ribonucleotide binding | GO:0032555 | 2.2 |
| receptor binding | GO:0005102 | 2.43 |
| purine ribonucleoside binding | GO:0032550 | 2.22 |
| ribonucleotide binding | GO:0032553 | 2.19 |
| GO:0008294 | 8.35 |